Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects.
Hyun Chul KimEunsol YangMu Seong BanYu-Kyong KimSung Hee HongJin-A JungIn-Jin JangSeung Hwan LeePublished in: Drug design, development and therapy (2023)
The sustained exposure of esomeprazole in the DR formulation led to well-maintained and higher acid inhibition compared to the EC formulation, especially during the night-time. These results suggest that the DR formulation can be an alternative formulation to the conventional EC formulation, expecting the potential of relieving nocturnal acid-related symptoms.